Publications by authors named "Carl Haslam"

Claim this Profile
S
Structure-activity studies of Streptococcus pyogenes enzyme SpyCEP reveal high affinity for CXCL8 in the SpyCEP C-terminal.
Max Pearson, Carl Haslam, Andrew Fosberry, Emma J Jones, Mark Reglinski

Sci Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing False Positives through the Application of Fluorescence Lifetime Technology: A Comparative Study Using TYK2 Kinase as a Model System.
Luke A Greenhough, Gabriella Clarke, Alexander N Phillipou, Faith Mazani, Bhumika Karamshi, Carl P Haslam

SLAS Discov· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Activity Relationship of the GPR55 Antagonist, CID16020046.
Andrew J Brown, Irene Castellano-Pellicena, Carl P Haslam, Paula L Nichols, Simon J Dowell

Pharmacology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate.
Sandra Kümper, Thorsten Gantke, Chao-Sheng Chen, Yasmina Soneji, Michael J Pattison, Carl Haslam

Biochem J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Investigation of the Best Buffers for Use in Screening by MALDI-Mass Spectrometry.
Jessica Chandler, Carl Haslam, Neil Hardy, Melanie Leveridge, Peter Marshall

SLAS Discov· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase.
Jonathan P Hutchinson, Paul Rowland, Mark R D Taylor, Erica M Christodoulou, Carl Haslam

Nat Commun· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
John Liddle, Benjamin Beaufils, Margaret Binnie, Anne Bouillot, Alexis A Denis, Carl P Haslam

Bioorg Med Chem Lett· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis.
Ann L Walker, Nicolas Ancellin, Benjamin Beaufils, Marylise Bergeal, Margaret Binnie, Carl P Haslam

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond.
Carl Haslam, John Hellicar, Adrian Dunn, Arne Fuetterer, Neil Hardy

J Biomol Screen· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis.
Damian J Mole, Scott P Webster, Iain Uings, Xiaozhong Zheng, Margaret Binnie, Carl Haslam

Nat Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Susan M Westaway, Alex G S Preston, Michael D Barker, Fiona Brown, Jack A Brown, Carl Haslam

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Susan M Westaway, Alex G S Preston, Michael D Barker, Fiona Brown, Jack A Brown, Carl Haslam

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry.
Denise M Lowe, Michelle Gee, Carl Haslam, Bill Leavens, Erica Christodoulou

J Biomol Screen· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Configuration of a high-content imaging platform for hit identification and pharmacological assessment of JMJD3 demethylase enzyme inhibitors.
Alpa Mulji, Carl Haslam, Fiona Brown, Rebecca Randle, Bhumika Karamshi

J Biomol Screen· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
Andrew J Brown, Dion A Daniels, Mumta Kassim, Sue Brown, Carl P Haslam

J Pharmacol Exp Ther· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.
Robert J Gleave, Paul J Beswick, Andrew J Brown, Gerard M P Giblin, Paul Goldsmith, Carl P Haslam

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.
Robert J Gleave, Paul J Beswick, Andrew J Brown, Gerard M P Giblin, Carl P Haslam

Bioorg Med Chem Lett· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Gerard M P Giblin, Andrew Billinton, Michael Briggs, Andrew J Brown, Iain P Chessell, Carl Haslam

J Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.
William L Mitchell, Gerard M P Giblin, Alan Naylor, Andrew J Eatherton, Brian P Slingsby, Carl P Haslam

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
Gerard M P Giblin, Celestine T O'Shaughnessy, Alan Naylor, William L Mitchell, Andrew J Eatherton, Carl P Haslam

J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
Cristiana Griffante, Andrew Green, Ornella Curcuruto, Carl P Haslam, Bryony A Dickinson

Br J Pharmacol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis